You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

~ Buy the LEVULAN (aminolevulinic acid hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR LEVULAN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Levulan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00524485 ↗ Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis Terminated National Cancer Institute (NCI) N/A 2005-05-01 RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, abnormal cells are killed. Photodynamic therapy using topical aminolevulinic acid may be effective against actinic keratosis. PURPOSE: This randomized clinical trial is studying how well different photodynamic therapy regimens using topical aminolevulinic acid work in treating patients with actinic keratosis.
NCT00524485 ↗ Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis Terminated Roswell Park Cancer Institute N/A 2005-05-01 RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, abnormal cells are killed. Photodynamic therapy using topical aminolevulinic acid may be effective against actinic keratosis. PURPOSE: This randomized clinical trial is studying how well different photodynamic therapy regimens using topical aminolevulinic acid work in treating patients with actinic keratosis.
NCT00706433 ↗ Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne Completed DUSA Pharmaceuticals, Inc. Phase 2 2007-03-01 The purpose of this study is to determine and compare the safety and efficacy of multiple broad area photodynamic therapy treatments with aminolevulinic acid (ALA-PDT) and vehicle (VEH-PDT) in subjects with moderate to severe facial acne vulgaris.
NCT00865878 ↗ ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients Terminated DUSA Pharmaceuticals, Inc. Phase 2 2009-05-01 The purpose of this study is to determine and compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) versus vehicle PDT (VEH-PDT) in the treatment of actinic keratoses (AK) and reduction of new non-melanoma skin cancer (NMSC) of the scalp or both forearms in solid organ transplant recipient subjects receiving chronic immunosuppressive therapy.
NCT01053000 ↗ Photodynamic Therapy With LevulanĀ® +/- Topical Retinoid Pre-Treatment In The Treatment Of Actinic Keratoses Completed Stewart, Roger H., M.D., P.A. N/A 2010-01-01 To determine and compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) following topical retinoid pre-treatment vs ALA-PDT with occlusion only (no pretreatment) in subjects with dorsal hand/forearm actinic keratoses, with an incubation time of 60 minutes, using blue light.
NCT01351519 ↗ A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors Terminated MultiCare Health System Research Institute Phase 2 2011-05-01 In this study subjects will be administered a single oral dose of Aminolevulinic Acid (ALA) prior to surgical resection of their brain tumor. The ALA ultimately causes brain tumor tissue to fluoresce or light up under ultraviolet light. During surgery an ultraviolet light in the microscope chain will be turned on. The tumor tissue will fluoresce bright pink allowing the surgeon to more easily differentiate tumor tissue from normal brain tissue. The aim of the study is to determine whether ALA and fluorescent visualization of tumor tissue improves the surgeon's ability to completely resect or remove the brain tumor.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Levulan

Condition Name

Condition Name for Levulan
Intervention Trials
Actinic Keratosis 9
Keratosis, Actinic 3
Actinic Keratoses 3
Basal Cell Nevus Syndrome 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Levulan
Intervention Trials
Keratosis, Actinic 17
Keratosis 17
Syndrome 3
Skin Neoplasms 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Levulan

Trials by Country

Trials by Country for Levulan
Location Trials
United States 87
Saudi Arabia 1
Finland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Levulan
Location Trials
California 12
Texas 9
Indiana 8
Florida 7
Virginia 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Levulan

Clinical Trial Phase

Clinical Trial Phase for Levulan
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2 13
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Levulan
Clinical Trial Phase Trials
Completed 20
Terminated 3
Not yet recruiting 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Levulan

Sponsor Name

Sponsor Name for Levulan
Sponsor Trials
DUSA Pharmaceuticals, Inc. 15
National Cancer Institute (NCI) 4
Case Comprehensive Cancer Center 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Levulan
Sponsor Trials
Other 22
Industry 16
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.